DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study

A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine

(2017) Sagar Munjal et al.   JOURNAL OF HEADACHE AND PAIN

Dodecylmaltoside Modulates Bicellular Tight Junction Contacts To Promote Enhanced Permeability

(2017) K. Gradauer et al.   MOLECULAR PHARMACEUTICS

A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine

(2016) Tiffini Voss et al.   CEPHALALGIA

A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults

(2016) Sagar Munjal et al.   HEADACHE

The Acute Treatment of Migraine in Adults: The American Headache Society Evidence Assessment of Migraine Pharmacotherapies

(2015) Michael J. Marmura et al.   HEADACHE

The therapeutic armamentarium in migraine is quite elderly

(2014) Paolo Martelletti   Expert Opinion on Drug Metabolism & Toxicology

Sumatriptan in clinical practice: effectiveness in migraine and the problem of psychiatric comorbidity

(2013) Flavia Napoletano et al.   EXPERT OPINION ON PHARMACOTHERAPY

Examination of Unmet Treatment Needs Among Persons With Episodic Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study

(2013) Richard B. Lipton et al.   HEADACHE

Sumatriptan succinate: pharmacokinetics of different formulations in clinical practice

(2012) Luana Lionetto et al.   EXPERT OPINION ON PHARMACOTHERAPY

Placebo response in the prophylaxis of migraine: A meta-analysis

(2007) Ana Macedo et al.   EUROPEAN JOURNAL OF PAIN